Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
Advertisement
Brandon TwyfordProstate Cancer Diagnostics | October 2, 2024
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
Read More
Cedric Pobel, MDmCSPC | September 26, 2024
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Jordana JampelmCSPC | September 11, 2024
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
Katy MarshallProstate Cancer Diagnostics | August 26, 2024
A previous study found 64Cu-SAR-bisPSMA to be safe and effective in identifying prostate cancer lesions in patients with BCR.
Brian Helfand, MD, PhDProstate Cancer Diagnostics | August 20, 2024
Dr. Helfand explores the potential of Clarity's 64Cu-SAR-bisPSMA agent for prostate cancer imaging.
Katy MarshallProstate Cancer Diagnostics | August 19, 2024
Black patients are often under-represented in oncology clinical trials.
Emily MenendezProstate Cancer Diagnostics | August 19, 2024
Stockholm3 is a blood-based test for the detection of prostate cancer that has demonstrated beneficial detection rates.
Adam Kinnaird, MD, PhDProstate Cancer Diagnostics | August 12, 2024
Dr. Kinnaird elaborates on some of the limitations of MRI and benefits of PET/CT staging for locoregional prostate cancer.
Emily MenendezProstate Cancer Diagnostics | August 2, 2024
PSMA PET/CT can act as a better alternative to MRI, but research on second-generation PSMA PET radioligands is limited.
Zachary BessetteProstate Cancer Diagnostics | July 24, 2024
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
Emily MenendezProstate Cancer Diagnostics | August 2, 2024
About 1 in 12 patients who undergo non-targeted prostate biopsy with a result of GGG 1 PC may have more aggressive cancer.
Katy MarshallProstate Cancer Diagnostics | August 2, 2024
Patients were sorted into groups based on modifiable lifestyle behaviors and genetic risk.
Emily MenendezProstate Cancer Diagnostics | August 2, 2024
Researchers trained and externally validated an AI system to detect Gleason grade group 2 or higher cancers.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Zachary BessetteProstate Cancer Diagnostics | June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Brandon TwyfordProstate Cancer Diagnostics | June 11, 2024
COBRA trial shows 64Cu-SAR-bisPSMA improves detection of recurrent prostate cancer with high specificity.
Tian Zhang, MDProstate Cancer Diagnostics | June 10, 2024
Dr. Zhang expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.
Katy MarshallProstate Cancer Diagnostics | May 21, 2024
Researchers found no differences between the proportion of distant metastases in the salvage PBRT and WPRT groups.
Eric Li, MDProstate Cancer Diagnostics | May 8, 2024
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Advertisement
Advertisement
Advertisement